T cells are indispensable for protective immune responses against pathogens and tumors. Naive T cells are actively maintained in a quiescent state to preserve their long-term survival and persistence1. Upon antigen stimulation, T cells exit quiescence, undergo clonal expansion and effector differentiation2. T cell receptor (TCR) signaling serves as the core process for initiating and regulating adaptive immune responses3. Upon specific recognition of peptide-major histocompatibility complex (pMHC) molecules presented on the surface of antigen-presenting cells (APCs), a cascade of signaling events is triggered, thereby driving clonal expansion and functional differentiation of T cells4,5,6.
The intensity of TCR stimulation, determined by key factors including antigen affinity, avidity, and concentration, plays a critical role in governing the magnitude of T cell activation, the acquisition of effector functions, and the differentiation trajectory toward distinct effector or memory T cell subsets7,8,9. Current in vitro models for investigating TCR-dependent T cell activation predominantly employ plate-bound or bead-conjugated anti-CD3 and anti-CD28 antibodies, which provide both TCR ligation and co-stimulatory signals simultaneously10,11. Although such systems are widely used, they typically utilize only a single, often saturating concentration of anti-CD3 antibody, permitting merely an all-or-nothing binary comparison of T cell activation, rather than capturing the dynamic range of TCR signal strengths achievable with a titrated gradient of stimuli12,13.
The protocol described herein provides a standardized and reproducible in vitro system to systematically evaluate how graded TCR signal strengths modulate activation, proliferation, and functional phenotypes of primary murine CD8+ T cells, using titrated anti-CD3 gradients (0.1–10 µg/mL) and a constant anti-CD28 (1 µg/mL). This approach centers on multiparameter flow cytometry that captures both upstream signaling—via intracellular phosphorylated S6 ribosomal protein (p-S6) as a readout of mechanistic target of rapamycin complex 1 (mTORC1) activity—and downstream cellular outcomes, including proliferation tracked by CTV dilution, activation surface markers (CD69, CD25, inducible T-cell costimulatory [ICOS], programmed cell death protein 1 [PD-1]), and effector molecule expression (Granzyme B, tumor necrosis factor-alpha [TNF-α]), over a time course from 6 to 48 h.
Our protocol employs a gradient concentration of plate-bound anti-CD3 antibodies to precisely modulate stimulation intensity, thereby mimicking the differential TCR binding avidity observed under physiological conditions. The method achieves high efficiency in TCR crosslinking and robust activation of primary resting T cells. The standardized coating procedure ensures uniform antibody distribution on the plate surface, leading to consistent stimulation across cells within the same batch and excellent experimental reproducibility. This format provides a cost-effective and operationally simple approach for T cell activation.
However, certain limitations of this approach should be acknowledged. Stimulation mediated by anti-CD3/CD28 antibodies differs markedly from the in vivo physiological context. Although experimental methods that use only agonistic anti-CD3 and anti-CD28 antibodies to assess T cell activation can provide effective readouts of activation, they fail to fully recapitulate the interactions between antigen-presenting cells and T cells, as well as the co-stimulatory microenvironment that occur under physiological conditions14.
Despite these limitations, this protocol offers a systematic and reproducible platform that serves as a valuable and accessible tool for investigating TCR signal strength-dependent T cell responses and can complement more complex antigen-specific models.